Previous 10 | Next 10 |
Nano cap Soligenix (NASDAQ: SNGX ) jumps 16% premarket on light volume in reaction to preliminary topline results from a Phase 3 clinical trial, FLASH , evaluating SGX301 (synthetic hypericin) in patients with cutaneous T-cell lymphoma (CTCL). More news on: Soligenix, Inc., ...
PRINCETON, N.J. , March 19, 2020 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today positive ...
PRINCETON, N.J. , Feb. 27, 2020 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that its ongoin...
Miami Beach, Florida--(Newsfile Corp. - February 20, 2020) - Soligenix may be nearing a transformative point in its history as data from its Phase 3 SGX301 (FLASH) trial to treat cutaneous T-cell lymphoma (CTCL) nears its release. The topline data from this late-stage study is expected in less...
Are These The Best Stocks To Trade Before The End Of February 2020? It goes without saying that investing in penny stocks comes with a certain level of risk. But at the same time, these cheap stocks can often generate substantial returns in a short period of time. Over the years, plenty of...
The following slide deck was published by Soligenix, Inc. in conjunction with this Read more ...
CounterPath (NASDAQ: CPAH ) +49% on securing five-year deal with Vodafone Fiji to extend superior quality voice services to consumers. More news on: CounterPath Corporation, Alpha Pro Tech, Ltd., NanoViricides, Inc., Stocks on the move, , Read more ...
The FDA designates Soligenix's (NASDAQ: SNGX ) RiVax (heat stable ricin toxin vaccine) for Fast Track review for the prevention of ricin intoxication. More news on: Soligenix, Inc., Healthcare stocks news, Stocks on the move, Read more ...
PRINCETON, N.J. , Feb. 13, 2020 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that its RiVax ...
PRINCETON, N.J. , Feb. 11, 2020 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that ...
News, Short Squeeze, Breakout and More Instantly...
NEW YORK and PRINCETON, N.J., Aug. 01, 2024 (GLOBE NEWSWIRE) -- PCG Digital -- Soligenix, Inc. (NASDAQ: SNGX), a late-stage biopharmaceutical company, is making significant strides in the treatment of Cutaneous T-Cell Lymphoma (CTCL) with its investigational drug, HyBryte™. In an exclusive...
2024-07-18 10:20:00 ET July 18, 2024 (Investorideas.com Newswire) Investorideas.com , a go-to investing platform releases the second of a two-part series looking at biotech/biopharma stocks, featuring Citius Pharmaceuticals, Inc. ( Nasdaq:CTXR ), a late-stage biopharmaceutical compa...
NEW YORK, July 15, 2024 (GLOBE NEWSWIRE) -- PRISM MarketView is pleased to announce an exclusive Q&A session with Dr. Ellen Kim, discussing the promising interim results of Soligenix's ( Nasdaq:SNGX ) HyBryte™ from the ongoing investigator-initiated study (IIS). HyBryte...